These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Which are the parameters to be controlled in platelet concentrates in order that they may be offered to the medical profession as a standardized product with specific properties? Vox Sang; 1981 Feb; 40(2):115-26. PubMed ID: 7233883 [No Abstract] [Full Text] [Related]
8. [Thrombopheresis with the CS-3000 cell separator. Changes in primary hemostasis in the donor and in concentrates in 8-day storage]. Budde U Beitr Infusionther Klin Ernahr; 1986; 15():75-81. PubMed ID: 3092802 [No Abstract] [Full Text] [Related]
9. Blood therapy: processing blood for transfusion. Kazak A Am J Nurs; 1979 May; 79(5):931-4. PubMed ID: 255072 [No Abstract] [Full Text] [Related]
10. [Blood components in the treatment of myelotoxic agranulocytosis and thrombopenia]. Gorodetskiĭ VM; Buachidze LN; Pashkov VV; Labetskaia IA; Fomina LI Ter Arkh; 1979; 51(9):83-9. PubMed ID: 494111 [No Abstract] [Full Text] [Related]
15. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. Moog R; Fröhlich A; Mayaudon V; Lin L J Clin Apher; 2004; 19(4):185-91. PubMed ID: 15597347 [TBL] [Abstract][Full Text] [Related]
16. The effects of combined platelet and leukapheresis on the blood coagulation system. Kisker CT; Strauss RG; Koepke JA; Maguire LC; Thompson JS Transfusion; 1979; 19(2):173-7. PubMed ID: 432930 [TBL] [Abstract][Full Text] [Related]